The treatment of small-round-cell tumors (SRCT) in adult patients remains a challenge to clinicians. In the present study, we analyzed the feasibility and efficacy of high-dose chemotherapy (HDCT) followed by autologous peripheral blood stem-cell rescue as a consolidation therapy exclusively for patients with good disease control through a single regimen of induction chemotherapy and local therapy. Twenty-one patients (12 females, median age 22.0 years) were analyzed, including seven cases with rhabdomyosarcoma (RMS) and 14 cases with Ewing's family tumors (EFT). Overall, survival was 46% and failure-free survival (FFS) was 33% at 3 years. Patients with EFT had better FFS than those with RMS, with an estimated 3-year FFS of 50% (Po0.01). There was a single case of possible treatment-related death and two cases of secondary malignancies. This study cannot conclusively determine the beneficial effects of HDCT for improving treatment outcomes in adult SRCTs due to the small number of subjects. However, study findings suggest that a subgroup of patients with EFT may obtain prolonged survival benefits from this therapy.
Introduction
Rhabdomyosarcoma (RMS) and Ewing's sarcoma family of tumors (EFTs), including Ewing's sarcoma of bone, extraskeletal Ewing's sarcoma and peripheral primitive neuroectodermal tumor, belong to the group of neoplasms commonly referred to as 'small round-cell sarcomas.' These tumors share a common morphologic histology and a similar treatment strategy consisting of multi-drug chemotherapy in combination with surgery and/or radiotherapy. 1, 2 A series of recent studies have reported improvements in outcomes of patients with the use of risk-adapted, intensive multimodal therapy, although the group of patients at high risk for treatment failure still remains. [3] [4] [5] Given that both diseases are considered to be chemotherapy-sensitive, dose intensification of chemotherapy is presumed to be a key factor in improving outcomes for patients with high risk factors. In particular, high-dose chemotherapy (HDCT) with stem cell rescue has been used in an attempt to improve clinical outcomes in high-risk patients. However, the impact of HDCT with stem cell rescue on the treatment of high-risk RMS or EFTs has yet to be established, as previous data have demonstrated inconsistent benefits. [6] [7] [8] [9] [10] [11] [12] It is of particular importance to identify subsets of highrisk patients for the purpose of risk stratification. Various studies have identified prognostic factors for patients with RMS or EFTs, including older age, presence of metastatic disease, tumor volume 4100 ml or axial site involvement. [13] [14] [15] [16] In particular, patient age is one of the strongest predictors of outcome both in EFTs and RMS. 17, 18 However, the management of adult patients with EFTs or RMS has been developed mainly from experiences with pediatric patients because of the rarity of the disease in adults. 19, 20 Poor outcomes in adult patients 21 may be attributed to the fact that an adult may not respond well to treatments designed for children.
On the basis of these considerations, the purpose of this clinical study was to investigate the effects of HDCT on overall survival (OS) and time to disease progression in adults and adolescent patients with EFTs and RMS. In this report, we present the results from a prospective pilot study of a treatment protocol consisting of induction chemotherapy, local treatment, followed by HDCT as a consolidation therapy.
Patients and methods

Eligibility criteria
Patients between 15 and 55 years of age with primary and high-risk RMS or EFTs, as previously defined, were considered eligible for the present study. The pathologic diagnosis was confirmed by conventional histopathological and immunohistochemical examinations. Molecular genetic studies were not routinely conducted to investigate specific chromosomal translocations. Routine radiological examinations before study enrollment included computerized tomography (CT) and/or magnetic resonance imaging (MRI) of the primary site, plain radiographs and CT scans of the chest and a 99 technetium-diphosphonate bone scan. A performance status of o2, along with adequate organ function, was required.
Adequate organ function was defined as an absolute neutrophil blood cell count 41.2 Â 10 9 /l, a platelet count 4100 Â 10 9 /l, a bilirubin level o2.0 mg/dl, a serum creatinine level o2.0 mg/dl, creatinine clearance 460 ml/ min and cardiac ejection fraction rate 450%.
Signed informed consent for the treatment was obtained from all patients or their legal guardian in accordance with our institutional review board guidelines.
Treatment protocol
The study treatment protocol included induction chemotherapy, local treatment (surgery and/or radiotherapy), followed by additional induction chemotherapy and, finally, HDCT with autologous peripheral blood stem-cell (APBSC) rescue. Induction chemotherapy consisted of a combination of four chemotherapeutic agents administered every 3 weeks, in modification of the CESS-86 regimen 22 ( Table 1) .
APBSCs were mobilized with the use of granulocyte colony-stimulating factor (G-CSF) after cycles 3 through 6 of the induction chemotherapy. Before stem cell harvesting, bone marrow aspirates and biopsies were performed to exclude bone marrow involvement of the tumor cells or abnormal myelopoietic functions. Harvesting was performed only when histological or cytological analyses indicated no evidence of tumor cells. A CD34 þ cell count 410 CD34 þ cells per ml was used as the harvest criterion. Total cell counts of CD34 þ cells 42.0 Â 10 6 /kg were required to proceed to further HDCT.
Imaging of the primary tumor by MRI and/or CT scanning was conducted after cycles 2 and 4 to aid decisions regarding local therapy, and once again before HDCT. Definitions of radiological antitumor effect were as follows: complete response (CR), no detectable tumors; partial response (PR), 450% reduction in measurable tumors; stable disease (SD), o50% reduction in measurable tumors and no new lesions; and progressive disease (PD), tumor growth or new lesions.
Local therapy was scheduled to be given after four courses of the induction chemotherapy, except when the primary tumor had been excised before the first visit to our hospital, or when the tumor was considered unresectable. Local therapy was planned individually, taking into consideration various factors such as tumor site, tumor size, tumor resectability, patients' performance status and expected disabilities after resection. Complete surgical resection was the theoretical goal, whenever feasible. Radiotherapy was prescribed in cases where the tumor was either unresectable or incompletely resectable, or where the surgical margin in the excised specimen proved to be inadequate.
Given that the aim of this study was to investigate the effect of HDCT as a consolidation therapy, patients were scheduled to be re-assessed after the induction chemotherapy with regard to the chemotherapeutic effect. If the patients were in CR or PR after four courses of induction chemotherapy, and had undergone definitive local therapy, they were considered to have minimal tumor burden and eligible for HDCT. If the patients were in SD, tumor excision without macroscopic residue was mandatory. If the patients were in PD, they were excluded from the study.
During the course of this study, two myeloablative regimens were used (Table 2) . APBSCs were re-infused on day 0, followed by daily administration of G-CSF for enhancement of myeloid reconstitution until the absolute neutrophil count remained above 1000/ml for 3 consecutive days. Toxicities Toxicities were scored in accordance with the NCI Common Terminology Criteria for Adverse Events (CTCAE).
Statistical methods OS rate was defined as the time interval from the date of HDCT to death. Failure-free survival (FFS) rate was defined as the time interval from the date of HDCT to disease progression, relapse, second malignancy or death. Survival analyses were conducted using the Kaplan-Meier method. 23 Comparisons of survival rates were performed using the log rank test.
Results
Patient characteristics
Twenty-five patients were enrolled into this study since 1995. Of the 25 enrolled patients (10 males and 15 females) with a median age of 22.0 years (15-35 years), eight patients (32%) had RMS, nine patients (36%) had EFT of the bone, and eight patients (32%) had EFT of the soft tissue. Twelve patients (48%) had metastatic lesions at the first presentation (Table 3) .
Post-induction response
All patients received four courses of induction chemotherapy. Two patients received alternative induction chemotherapy before the prescribed regimen (VAIA) because of their huge tumor size (Case 4) and presence of disseminated intravascular coagulation at the first presentation (Case 24).
Twenty-four patients were assessable after induction chemotherapy, excluding one patient who had undergone radical surgery as an initial treatment. The overall response rate was 75% (18 of 24 patients), with 17% achieving CR (four out of 24), 63% achieving PR (15 out of 24), 13% achieving SD (two out of 24) and 8% resulting PD (two out of 24).
Four out of the 25 enrolled patients (16%) did not receive HDCT because two of them declined after finishing induction chemotherapy and the other two had disease progression during the induction chemotherapy. The remaining 21 patients were considered eligible for the HDCT.
The average CD34 þ cell count at PBSCT was 4.21 Â 10 6 CD34 þ cells/kg body weight (range:1.7-14.9). The average number of harvesting performed was 1.8 (range 1-3). Stem cell harvesting in patients who had bone and/or bone marrow metastases at the first presentation was performed after cycles 5 or 6 to minimize tumor cell contamination, although there were no patients whose bone marrow aspirates or biopsies indicated tumor cell involvement.
Outcome
The median follow-up was 41.0 months (range 10-105 months) for the 21 patients who received HDCT. The final outcome of these patients included 13 DOD (died of disease), seven CDF (continuous disease free) and one NED (no evidence of disease). There were no AWD (alive with disease) cases at the time of this study. The median OS and FFS from the date of PBSC reinfusion was 41.2 months (range 0-105) and 6.0 months (range 0-105), respectively. Figure 1 shows the KaplanMeier survival curves for OS ( Figure 1a ) and FFS (Figure 1b) . The survival curves indicate that none of the patients relapsed beyond 16 months after HDCT. Figure 2 shows the Kaplan-Meier survival curves for OS (Figure 2a ) and FFS (Figure 2b ) in patients with EFT and RMS. FFS for patients with EFT was significantly better compared with those with RMS. However, OS was not significantly different between the two groups of patients. Figure 3a and b show that survival estimates in patients with (M1) and without (M0) metastatic disease at the time of enrollment was significantly different with regard to FFS, but not for OS. Survival estimates comparing HDCT regimens and local treatment modalities were also performed, although there were no significant differences in either OS or FFS.
Toxicity
All patients who received HDCT experienced CTCAE grade 4 leukopenia, neutropenia and thrombocytopenia, which subsequently improved with stem cell re-infusion. One patient (Case 2) presented rapidly progressing left ventricular systolic dysfunction and pneumonitis on day 7, which resulted in a fatal cardiac arrest on day 8. As the patient's family did not consent to an autopsy, the definitive cause of the sudden cardiac arrest remains unknown. Nonetheless, it is suspected that cyclophosphamide (CPA)-induced or viral myocarditis was the possible cause.
Treatment-related second malignancy was observed in two patients (Cases 6 and 15). One case (Case 6: myelodysplastic syndrome (MDS)) occurred 34 months after the initial diagnosis of shoulder-girdle RMS with extensive bone/bone marrow metastases. The patient was treated with chemotherapy, followed by allograft bone marrow transplantation, which successfully resulted in complete remission of the MDS. The patient, however, died 51 months after the occurrence of the secondary MDS from graft-versus-host disease-induced pulmonary fibrosis. The second case (Case 15: AML) was diagnosed 23 months after the initial diagnosis of pleural EFT. This patient also received chemotherapy followed by allograft bone marrow transplantation. Given that AML recurred shortly after BM transplantation, the patient died 16 months after the occurrence of the secondary AML.
Discussion
To date, only a small number of studies have examined the clinical significance of HDCT exclusively in adult patients with RMS or EFT. 24, 25 Older age is known to be a significantly negative prognostic factor for both diseases, as previous studies have revealed. [15] [16] [17] [18] The present study was conducted at a single institution using a single-arm condition and, as such, we were unable to draw any conclusive results. However, this study demonstrated that a HDCT approach is feasible in subsets of adult patients with RMS or EFT. It should be noted that the median age (22.0 years) of the patients was considerably higher than in previously reported studies.
This study was designed to examine patients with either RMS or EFT, given that treatment strategies for high-risk subsets of both diseases are very similar. The results indicate that RMS patients had very poor outcomes, with no failure-free cases at observation, whereas EFT patients had favorable outcomes, with an FFS rate of 50%. Our findings are consistent with those of Bertuzzi et al., 12 who also investigated the effects of HDCT in adults. Both study findings suggest that, compared with EFT patients, high-risk RMS patients should not be exposed to intensive treatment using HDCT and PBSC rescue.
Most studies using APBSC as hematopoietic rescue included a mobilization phase with a regimen distinct from the induction phase. In the present study, a sufficient number of APBSCs were harvested after induction chemotherapy with G-CSF mobilization. Two out of 20 patients received additional mobilization chemotherapy consisting of a single agent. Harvesting APBSCs in the induction phase resulted in fewer chemotherapeutic agents and shorter treatment duration, both of which benefit patients.
Treatment intensification involves considerable risks. [26] [27] [28] In the present study, one possible case of treatment-related fatal adverse effect and two cases of secondary malignancy (one MDS and one AML) were observed. Treatmentrelated deaths in three out of 21 patients (14%) strongly suggest that such intensive treatment must be restricted to patients with a high risk of mortality. The role of HDCT supported by stem cell rescue as a consolidation therapy for high-risk EFT and RMS patients has yet to be determined conclusively. Numerous reports have described disappointing survival outcomes in patients with EFT and RMS regarding the efficacy of HDCT. [7] [8] [9] [10] [11] [12] [13] However, it is difficult to deny completely the role of HDCT in patients with primary high-risk or recurrent diseases and abandon the application of this therapy, especially, as there are only a few new drugs that have been proven effective for refractory conditions. It has also been noted repeatedly that small studies conducted within a single institution cannot provide any definitive conclusions as to whether HDCT should be retained as a component of therapy for patients with high-risk EFT and RMS. A multicenter, prospective, randomized trial must be conducted to answer these difficult questions, although it should be difficult to carry out such a study due to the rare nature of these diseases. Oberlin et al. 29 recently reported on a nation-wide and multicenter scale that consolidation HDCT is feasible and may provide benefits for some EFT patients with refractory conditions. 
